Author

Joss de Wet

Observed names: JJ de Wet, Joss De Wet, Joss J De Wet

Observed institutions: University of British Columbia, Spectrum Health

OpenAlex ID: A5114037039

Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial

2020 · Kenneth H Mayer, Jean-Michel Molina, et al. · The Lancet · 447

Quality of Life in Patients Treated with First-Line Antiretroviral Therapy Containing Nevirapine And/Or Efavirenz

2004 · the 2NN study group, Frank van Leth, et al. · Antiviral Therapy · 27

Plasma HIV-1 RNA decline within the first two weeks of treatment is comparable for nevirapine, efavirenz, or both drugs combined and is not predictive of long-term virologic efficacy: A 2NN substudy.

2005 · Frank van Leth, Casper B Huisamen, et al. · PubMed · 15

Recognizing Cognitive and Psychiatric Changes in the Post‐Highly Active Antiretroviral Therapy Era

2012 · Adriana Carvalhal, Jean-Guy Baril, et al. · Canadian Journal of Infectious Diseases and Medical Microbiology · 7

Quality of Life and Treatment Satisfaction in People with HIV Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide: Pooled Analysis from Observational Cohort Studies

2025 · Andrea Antinori, Yoshiyuki Yokomaku, et al. · Infectious Diseases and Therapy · 4

Twelve-month effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide in people with HIV from the Canadian cohort of the observational BICSTaR study

2024 · Alexander Wong, Jason Brunetta, et al. · Medicine · 4

Randomized Controlled Trial of Once-Daily Tenofovir, Lamivudine, and Lopinavir/Ritonavir Versus Remaining on the Same Regimen in Virologically Suppressed HIV-Infected Patients on Their First PI-Containing HAART Regimen

2007 · Mona R. Loutfy, Nabil Ackad, et al. · HIV Clinical Trials · 3

Real-World Effectiveness and Tolerability of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in Treatment-Experienced (TE) People with HIV with a History of CKD

2023 · Ansgar Rieke, Joss De Wet, et al. · Journal of the American Society of Nephrology · 1

1252. A Real-World Observational Study on HIV-Infected Patients who Switched from Nevirapine + 2 Nucleoside Reverse Transcriptase Inhibitors to Dolutegravir/Lamivudine in British Columbia, Canada

2022 · Joss de Wet, Joann K Ban, et al. · Open Forum Infectious Diseases

319. SWORD 1 and 2: Switch from TDF Containing Regimen to DTG+RPV Maintains Bone Mineral Density and Decreases Bone Turnover Markers Over 148 Weeks

2019 · Lesley Kahl, Grace A McComsey, et al. · Open Forum Infectious Diseases

Works count: 10

Citation count: 508

H-index: 4

I10-index: 3